Evaluation of adverse drug reactions in medical intensive care units

European Journal of Clinical Pharmacology

Volumn 69, Issue 1, 2013, Pages 119-131

  Park, Sojin ^a   In, Yongwon ^a   Suh, Gee Young ^b   Sohn, Kieho ^c   Kim, Eunyoung ^d  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Kyungsung University   (South Korea)

^d Chungnam National University   (South Korea)

Author keywords

Adverse drug reaction; Detection signals; Intensive care units; Interventions

Indexed keywords

ALLOPURINOL; AMILORIDE; AMINOGLYCOSIDE; AMPHOTERICIN B; ASPARAGINASE; CARBAMAZEPINE; CIMETIDINE; COLISTIMETHATE; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; DIURETIC AGENT; ETHAMBUTOL; FAMOTIDINE; HEPARIN; INDOMETACIN; LAPATINIB; LINEZOLID; METHYLPREDNISOLONE; MIDAZOLAM; PENICILLIN DERIVATIVE; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SPIRONOLACTONE; TACROLIMUS; TIGECYCLINE; UNINDEXED DRUG; VALSARTAN; VANCOMYCIN;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; AUTOMATION; CHILD; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHARMACIST; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSIS; RASH; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEDATION; SIDE EFFECT; SIGNAL DETECTION; TACHYCARDIA; THROMBOCYTOPENIA; ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DRUG TOXICITY; FEMALE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 84872293703     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1318-2     Document Type: Review

References (38)

1. World Health Organization for Safety of Medicines (2002) A guide to detecting and reporting adverse drug reactions. WHO, Geneva
2. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of ADR in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 279:1000-1005
3. Moore N, Lecointre D, Noblet C, Mabille M (1998) Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 45:301-308
4. WHO Collaborating Centre for International Drug Monitoring Safety Monitoring of Medicinal Products (2000) Guidelines for setting up and running a pharmacovigilance centre. UMC, WHO, EQUUS
5. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL (1997) Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 25:1289-1297
6. Dormann H, Krebs S, Muth-Selbach U, Criegee-Rieck M, Radespiel-Troger M, Levy M, Hahn EG, Brune K, Schneider HT (2001) Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther 15:171-180
7. Spriet I, Meersseman W, Jan DH, Winckelmann SV, Wilmer A, Willems L (2009) Mini-series II. Clinical aspects: clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 35:603-612
8. Kane-Grill SL, Devlin JW (2006) Adverse drug event reporting in intensive care units: a survey of current practices. Ann Pharmacother 40:1267-1273
9. Gandhi TK, Seger DL, Bates DW (2007) Identifying drug safety issues: from research to practice. Int J Qual Health Care 12:69-76
10. Rozich JD, Haraden CR, Resar RK (2003) Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care 12:194-200
11. Bates DW, Leape LL, Petrycki S (1993) Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 8:349-394
12. Hwang SH, Lee S, Koo HK, Kim Y (2008) Evaluation of a computer-based adverse-drug-event Monitor. Am J Health Syst Pharm 65:2265-2272
13. Kim EY, Kim SM, Chung SY (2006) Implementation and evaluation of concurrent computerized surveillance system (CSS) for the detection and prevention of adverse drug reactions. J Kor Soc Health Syst Pharm 23(3):179-191
14. Ernst AA, Weiss SJ, Sullivan A 4th, Sarangarm D, Rankin S, Fees M, Sarangarm P (2011) On-site pharmacists in the ED improve medical errors. Am J Emerg Med. doi: 10.1016/j.ajem.2011.05.002
15. Erstad BL, Haas CE, O'Keeffe T, Hokula CA, Parrinello K, Theodorou AA (2011) Interdisciplinary patient care in the intensive care unit: focus on the pharmacist. Pharmacotherapy 31(2):128-137
16. Meidl TM, Woller TW, Iglar AM, Brierton DG (2008) Implementation of pharmacy services in a telemedicine intensive care unit. Am J Health Syst Pharm 65(15):1464-1469
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probabiliting of adverse drug reactions. Clin Pharmacol Ther 30(2):239-245
18. Hong KS, Park BJ, Sin SG, Yang JS, Lee SM, Kim YN (2002) Development of a Korean algorithm for causality assessment of adverse drug reactions. J Kor Soc Clin Pharmacol Ther 10:129-142
19. Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F, Royer RJ (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 2:1056-1058
20. Danan G, Benichou C (1998) Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323-1330
21. UMC (2009) Uppsala Monitoring Center home page. http://www.who-umc.org/ umc.html (accessed on 1 June 2009)
22. Hartwig SC, Denger SD, Schneider PJ (1991) Severity-indexed, incident report-based medication error-reporting program. Am J Hosp Pharm 48(12):2611-2616
23. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. J Am Med Assoc 277(4):301-306
24. Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27(6):538
25. Thomson Reuters (2009) Micromedex healthcare series internet database. http://www.micromedex.com/ (accessed September 29, 2009)
26. Brennan TA, Leape LL, Laird NM (1991) Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 324:370-376
27. Kopp BJ, Erstad BL, Allen ME, Theodorou AA, Priestley G (2006) Medication errors and adverse drug events in an ICU: direct observation approach for detection. Crit Care Med 34(2):415-425
28. Dubaybo BA, Dingell JD (2005) Adverse drug reactions in the ICU: lessons learned. Chest 128:1100-1101
29. Kohn LT, Corrigan J, Donaldson MA (1999) To err is human: building a safer health system. National Academies Press, Washington DC
30. Leape LL, Brennan TA, Lawthers AG (1991) The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 324:377-384
31. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL (1997) The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. J Am Med Assoc 277:307-311
32. Reis AM, Cassiani SH (2011) Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol 67(6):625-632
33. Lee SM, Hahn SK, Park BJ (2005) Signal detection and causality evaluation for pharmacovigilance. J Kor Soc Clin Pharmacol Ther 13:121-133
34. Son YM, Lee JR, Roh JY (2011) Causality assessment of cutaneous adverse drug reactions. Ann Dermatol 23(4):432-438
35. Hwang SH, Kim EY, Lee YS (2005) Implementation and evaluation of the computerized surveillance system to identify adverse drug events: pilot study. J Kor Soc Health Syst Pharm 22(2):118-136
36. Bates DW, Spell N, Cullen DJ (1997) The costs of adverse drug events in hospitalized patients. N Engl J Med 277(4):307-311
37. Egger SS, Drewe J, Schlienger RG (2003) Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58(11):773-778
38. Annette VDi, Brian RC, Daniel WB (2007) Vancomycin-induced immune thrombocytopenia. N Engl J Med 356:904-910